Clinical Trials Logo

Filter by:
NCT ID: NCT05619861 Recruiting - Multiple Myeloma Clinical Trials

CAR-T Cells in the Treatment of Malignant Hematological Tumors

Start date: April 27, 2020
Phase: N/A
Study type: Interventional

To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors

NCT ID: NCT05619848 Completed - Clinical trials for Spinal Stenosis Lumbar

Effect of Paravertebral Muscle Fat Infiltration on Rocuronium Use in Lumbar Surgery

RUILS
Start date: October 25, 2022
Phase: Early Phase 1
Study type: Interventional

To investigate the effect of different degrees of fat infiltration on rocuronium use in lumbar surgery was monitored by trapezius muscle relaxation.

NCT ID: NCT05619120 Recruiting - Clinical trials for Giant T-wave Electrical Alternans

The Effect of Late Na Current Blocker Mexiletine on Giant T-wave Electrical Alternans(STOP-TWA)

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The electrocardiogram is one of the most basic tests for cardiovascular disease. T wave alternans (TWA), which reflects abnormal ventricular repolarization, can easily trigger ventricular tachycardia (VT) and ventricular fibrillation (VF), which are important warning clues for sudden cardiac death (SCD). The late sodium current (INaL) is an important component of the frequency-dependent regulation of cardiac repolarization, and various causes of delayed repolarization can increase INaL. Our study on long QT syndrome (LQTS) found that INaL abnormalities can lead to abnormal myocardial repolarization, producing a giant TWA that triggers VT and VF. VT and VF, and INaL inhibition by the INaL blocker mexilate can terminate this process. This suggests that pharmacological blockade of INaL may be a potential target for the prevention of SCD by ameliorating the different causes of giant TWA and its triggering ventricular arrhythmic events. In this study, we propose to randomize patients with VT/VF triggered by giant TWA to conventional treatment and conventional treatment adds mexiletine treatment to compare the effects of the two treatment regimens on giant TWA and its triggered nonsustained VT, sustained VT, and VF; at the same time, we will compare the effects of mexiletine on giant TWA and its triggered ventricular arrhythmias of various etiologies by intra-group control before and after treatment. The safety and efficacy of the treatment of TWA and its triggered ventricular arrhythmias are compared.

NCT ID: NCT05619068 Recruiting - Clinical trials for Cognitive Impairment

The Evolution and Prognosis of Moyamoya Disease

Start date: September 1, 2022
Phase:
Study type: Observational [Patient Registry]

To investigate the evolution of imaging appearances and cognitive function of Moyamoya disease (MMD) and to establish a prognosis evaluation system based on imaging biomarkers in MMD. The study may be helpful to optimize and improve the diagnosis and pretreatment assessment of MMD, and provide an important theoretical supplement to the existing guidelines for the management of MMD.

NCT ID: NCT05619055 Recruiting - Clinical trials for Necrotizing Enterocolitis of Newborn

The Intestinal Dysbacteriosis in the Pathogenesis of Necrotizing Enterocolitis

Start date: November 5, 2022
Phase:
Study type: Observational

Study Description The goal of this observational study is to detect intestinal flora and the metabolic products in premature infants diagnosed as necrotizing enterocolitis. The main questions it aims to answer are: - 1. Whether there is intestinal flora in the stool of premature infants. - 2. Are there dysregulated intestinal flora and their metabolic products in premature infants diagnosed as necrotizing enterocolitis. - 3. The detailed role and underlying mechanism of the intestinal dysbacteriosis and the metabolic products in premature infants diagnosed as necrotizing enterocolitis. Participants, premature infants diagnosed as necrotizing enterocolitis (NEC group), will be asked to collect stool (usually 2 times) for intestinal flora analysis. If there is a comparison group: Researchers will compare premature infants without necrotizing enterocolitis (control group) to see if their intestinal flora and the metabolic products also changed as their NEC counterparts.

NCT ID: NCT05618821 Recruiting - Gastric Cancer Clinical Trials

Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer

Start date: June 3, 2022
Phase: Phase 2
Study type: Interventional

Patients with resectable remnant gastric cancer were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in guiding laparoscopic lymph node dissection for remnant gastric cancer by comparing injection ICG group and non-injection ICG group.

NCT ID: NCT05618535 Completed - Clinical trials for Acute Ischemic Stroke

Effect of Body Position on Hemodynamics in Patients With Acute Ischemic Stroke Undergoing Ultra-early Reperfusion Therapy

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The aim of this study was to determine the differences in hemodynamics between different positions in patients undergoing ultra-early reperfusion therapy.

NCT ID: NCT05618470 Recruiting - Dry Eye Syndromes Clinical Trials

Wumeiwan Jiawei Fang Use in Patients With Blepharospasm

Start date: January 12, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy and safety of Jing Fang Wu Mei Wan Jiawei Fang in the treatment of idiopathic blepharospasm using a clinical randomized controlled trial method.

NCT ID: NCT05618379 Active, not recruiting - Clinical trials for Muscular Atrophy, Spinal

Adult Spinal Muscular Atrophy (SMA) China Registry

Start date: January 6, 2023
Phase:
Study type: Observational [Patient Registry]

The primary objective of the study is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA).

NCT ID: NCT05618340 Active, not recruiting - Clinical trials for Paroxysmal Atrial Fibrillation

PFA for Paroxysmal Atrial Fibrillation

Start date: September 26, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to verify the safety and efficacy of the cardiac pulse ablation system in paroxysmal atrial fibrillation to provide the basis for product registration and clinical application. The trial will be conducted at a clinical center with appropriate clinical cases, and paroxysmal atrial fibrillation ablation procedures will be performed by an authorized investigator using the trial product. The effectiveness and safety of the cardiac pulse ablation system in the treatment of paroxysmal atrial fibrillation will be verified by collecting the treatment success rate, immediate ablation success rate, procedure time and device use evaluation within 12 months after the procedure.